These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 9021215

  • 1. Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes.
    Aldridge KE, Ashcraft D, Bowman KA.
    Antimicrob Agents Chemother; 1997 Feb; 41(2):484-7. PubMed ID: 9021215
    [Abstract] [Full Text] [Related]

  • 2. Comparison of activities of trovafloxacin (CP-99,219) and five other agents against 585 anaerobes with use of three media.
    Hecht DW, Osmolski JR.
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S44-50. PubMed ID: 8953106
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of gemifloxacin (SB 265805) against anaerobes.
    Goldstein EJ, Citron DM, Warren Y, Tyrrell K, Merriam CV.
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2231-5. PubMed ID: 10471570
    [Abstract] [Full Text] [Related]

  • 4. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.
    Wexler HM, Molitoris E, Molitoris D, Finegold SM.
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2232-5. PubMed ID: 8878617
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.
    Spangler SK, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2471-6. PubMed ID: 7840591
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Susceptibility of 497 clinical isolates of gram-negative anaerobes to trovafloxacin and eight other antibiotics.
    Rotimi VO, Mokaddas EM, Jamal WY, Khodakhast FB, Verghese TL, Sanyal SC.
    J Chemother; 1999 Oct; 11(5):349-56. PubMed ID: 10632380
    [Abstract] [Full Text] [Related]

  • 13. [Activity of trovafloxacin and ten other antimicrobials against gram negative anaerobic bacilli].
    Chávez M, García López JL, Coronilla J, Bernal S, Valverde A, Martín Mazuelos E.
    Rev Esp Quimioter; 1998 Dec; 11(4):349-52. PubMed ID: 9990149
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vitro activities of three of the newer quinolones against anaerobic bacteria.
    Wexler HM, Molitoris E, Finegold SM.
    Antimicrob Agents Chemother; 1992 Jan; 36(1):239-43. PubMed ID: 1317149
    [Abstract] [Full Text] [Related]

  • 19. In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.
    Wexler HM, Molitoris E, Reeves D, Finegold SM.
    J Antimicrob Chemother; 1994 Oct; 34(4):579-84. PubMed ID: 7868409
    [Abstract] [Full Text] [Related]

  • 20. In vitro susceptibility of anaerobes to quinolones in the United States.
    Hecht DW, Wexler HM.
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S2-8. PubMed ID: 8953099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.